Cargando…

A phase 1 study comparing the proposed biosimilar BS‐503a with bevacizumab in healthy male volunteers

This is a randomized, double‐blind, single‐dose, parallel group phase 1 study to assess pharmacokinetic similarity, safety, and tolerability of BS‐503a, a proposed bevacizumab biosimilar. A total of 114 male healthy subjects were randomized (1:1) to receive a single 3 mg/kg intravenous dose of eithe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tajima, Naoyuki, Martinez, Alberto, Kobayashi, Fumiaki, He, Ling, Dewland, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368956/ https://www.ncbi.nlm.nih.gov/pubmed/28357118 http://dx.doi.org/10.1002/prp2.286

Ejemplares similares

A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers
por: Knight, Beverly, et al.
Publicado: (2016)

A randomized, single-dose, pharmacokinetic equivalence study comparing MB02 (proposed biosimilar) and reference bevacizumab in healthy Japanese male volunteers
por: Eto, Takashi, et al.
Publicado: (2021)

A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers
por: Shin, Donghoon, et al.
Publicado: (2020)

A Phase I, Randomized, Single-Dose Study Evaluating the Biosimilarity of TAB008 to Bevacizumab in Healthy Volunteers
por: Wang, Jin, et al.
Publicado: (2019)

A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers
por: Sinn, Angela, et al.
Publicado: (2021)

A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
por: Hummel, Matthew, et al.
Publicado: (2021)

Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab
por: Cao, Di, et al.
Publicado: (2023)

A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects
por: Liu, Ya-nan, et al.
Publicado: (2020)

SB8: A Bevacizumab Biosimilar
por: Syed, Yahiya Y.
Publicado: (2020)

MYL-1402O: A Bevacizumab Biosimilar
por: Lee, Arnold
Publicado: (2021)

Correction to: SB8: A Bevacizumab Biosimilar
por: Syed, Yahiya Y.
Publicado: (2020)

A Randomized, Double-Blind, Single-Dose Study Comparing the Biosimilarity of HOT-1010 With Bevacizumab (Avastin®) in Chinese Healthy Male Subjects
por: Huang, Kai, et al.
Publicado: (2021)

Clinical Evaluation of Humira(®) Biosimilar ONS-3010 in Healthy Volunteers: Focus on Pharmacokinetics and Pharmacodynamics
por: Dillingh, Marlous R., et al.
Publicado: (2016)

Bioavailability of ibuprofen following oral administration of standard ibuprofen, sodium ibuprofen or ibuprofen acid incorporating poloxamer in healthy volunteers
por: Dewland, Peter M, et al.
Publicado: (2009)

Development of the Drug Product Formulation of the Bevacizumab Biosimilar PF-06439535 (Bevacizumab-bvzr)
por: Ingram, Rebecca L., et al.
Publicado: (2023)

A randomized, double‐blind, comparative study of the pharmacodynamics and pharmacokinetics of GP40141 (romiplostim biosimilar) and reference romiplostim in healthy male volunteers
por: Makarenko, Igor, et al.
Publicado: (2023)

Safety and efficacy of bevacizumab biosimilar in recurrent/ progressive glioblastoma
por: Kumar, Gunjesh, et al.
Publicado: (2021)

Correction to: MYL-1402O: A Bevacizumab Biosimilar
por: Lee, Arnold
Publicado: (2022)

A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men
por: Markus, Richard, et al.
Publicado: (2017)

A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjects
por: Hanes, Vladimir, et al.
Publicado: (2018)

Confirmation of Biosimilarity in a Pharmacokinetic/Pharmacodynamic Study in Healthy Volunteers for an Analytically Highly Similar Pegfilgrastim
por: Desai, Kalpna, et al.
Publicado: (2016)

Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers
por: Choi, Chungam, et al.
Publicado: (2018)

Measurement of the phase of $B_s$ mixing with $B_s \to \phi \phi$
por: Needham, M
Publicado: (2014)

Correction to: A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men
por: Markus, Richard, et al.
Publicado: (2017)

LZM008, a proposed tocilizumab biosimilar: Pharmacokinetics, safety, and immunogenicity profiles compared with ACTEMRA(®) in Chinese healthy male subjects
por: Cao, Guoying, et al.
Publicado: (2023)

Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab
por: Seo, Neungseon, et al.
Publicado: (2018)

Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?
por: Monk, Bradley J., et al.
Publicado: (2017)

Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars
por: Rosen, Lee S., et al.
Publicado: (2017)

The Totality of Evidence and Use of ABP 215, a Biosimilar to Bevacizumab
por: Goldschmidt, Jerome, et al.
Publicado: (2020)

Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors
por: Farhan, Roiya, et al.
Publicado: (2017)

Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double‐blind, parallel‐controlled, phase 1 study
por: Zhang, Hong, et al.
Publicado: (2021)

Population pharmacokinetics of olprinone in healthy male volunteers
por: Kunisawa, Takayuki, et al.
Publicado: (2014)

A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab
por: Demarchi, Martin, et al.
Publicado: (2021)

Measurement of the $B_s^0$ mixing phase using $B_s^0 → ϕϕ$
por: Needham, M
Publicado: (2016)

Safety of Intravitreal Injection of Stivant, a Biosimilar to Bevacizumab, in Rabbit Eyes
por: Lashay, Alireza, et al.
Publicado: (2020)

Intraocular Injection of StivantⓇ (A Biosimilar to Bevacizumab): A Case Series
por: Mirshahi, Ahmad, et al.
Publicado: (2021)

Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer
por: Socinski, Mark A., et al.
Publicado: (2021)

Physicochemical stability of PF-06439535 (bevacizumab-bvzr; Zirabev(®)), a bevacizumab biosimilar, under extended in-use conditions
por: Weiser, Sarah, et al.
Publicado: (2022)

A phase I study comparing the pharmacokinetics of the biosimilar (RD12014) with liraglutide (Victoza) in healthy Chinese male subjects
por: Zhou, Ruirui, et al.
Publicado: (2022)

A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects
por: Hanes, Vladimir, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_tp1v4hgets57o2t55a8qjhhsng